✓ Independent editorial reviews of U.S. telehealth providers · Updated June 1, 2026 · Educational only — not medical advice
Clinical Reference · Updated 2026-06-01

SUSTAIN Trial Results

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

Clinical referencePubMed-linkedUpdated 2026-06-01
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-01

Overview

SUSTAIN-6 (NEJM 2016, PMID 27633186) cardiovascular safety in T2D + high CV risk: 26% MACE reduction. Led to Ozempic's FDA approval.

PubMed citations

Related clinical pages